BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 26223461)

  • 21. The pathogenesis of classical Hodgkin's lymphoma: what can we learn from analyses of genomic alterations in Hodgkin and Reed-Sternberg cells?
    Janz M; Mathas S
    Haematologica; 2008 Sep; 93(9):1292-5. PubMed ID: 18757849
    [No Abstract]   [Full Text] [Related]  

  • 22. Nivolumab in the Treatment of Hodgkin Lymphoma.
    Ansell SM
    Clin Cancer Res; 2017 Apr; 23(7):1623-1626. PubMed ID: 27881581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting Immune System Alterations in Hodgkin Lymphoma.
    Grover NS; Savoldo B
    Curr Hematol Malig Rep; 2017 Aug; 12(4):358-369. PubMed ID: 28780614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reed-Sternberg-Like Cells in Non-Hodgkin Lymphomas.
    Gomez-Gelvez JC; Smith LB
    Arch Pathol Lab Med; 2015 Oct; 139(10):1205-10. PubMed ID: 26414463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proliferation profile of classical Hodgkin's lymphomas. Increased expression of the protein cyclin D2 in Hodgkin's and Reed-Sternberg cells.
    Bai M; Tsanou E; Agnantis NJ; Kamina S; Grepi C; Stefanaki K; Rontogianni D; Galani V; Kanavaros P
    Mod Pathol; 2004 Nov; 17(11):1338-45. PubMed ID: 15354186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hodgkin's lymphoma: molecular targets and novel treatment strategies.
    Yazbeck V; Georgakis GV; Wedgwood A; Younes A
    Future Oncol; 2006 Aug; 2(4):533-51. PubMed ID: 16922620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Checkpoint inhibitors in Hodgkin's lymphoma.
    Jezeršek Novaković B
    Eur J Haematol; 2016 Apr; 96(4):335-43. PubMed ID: 26560962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma.
    Bräuninger A; Hansmann ML; Strickler JG; Dummer R; Burg G; Rajewsky K; Küppers R
    N Engl J Med; 1999 Apr; 340(16):1239-47. PubMed ID: 10210707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New drugs and targeted treatments in Hodgkin's lymphoma.
    Provencio M; Sánchez A; Sánchez-Beato M
    Cancer Treat Rev; 2014 Apr; 40(3):457-64. PubMed ID: 24095205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LGALS3 as a prognostic factor for classical Hodgkin's lymphoma.
    Koh YW; Jung SJ; Park CS; Yoon DH; Suh C; Huh J
    Mod Pathol; 2014 Oct; 27(10):1338-44. PubMed ID: 24603587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suppression of the LMP2A target gene, EGR-1, protects Hodgkin's lymphoma cells from entry to the EBV lytic cycle.
    Vockerodt M; Wei W; Nagy E; Prouzova Z; Schrader A; Kube D; Rowe M; Woodman CB; Murray PG
    J Pathol; 2013 Aug; 230(4):399-409. PubMed ID: 23592216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Classical Hodgkin's lymphoma associated with Langerhans cell histiocytosis: multiagent chemotherapy resulted in histologic resolution of both the classical Hodgkin's lymphoma and Langerhans cell proliferation components.
    Greaves WO; Bueso-Ramos C; Fayad L
    J Clin Oncol; 2011 Feb; 29(4):e76-8. PubMed ID: 21041711
    [No Abstract]   [Full Text] [Related]  

  • 33. Transforming growth factor beta 1 messenger RNA in Reed-Sternberg cells in nodular sclerosing Hodgkin's disease.
    Newcom SR; Gu L
    J Clin Pathol; 1995 Feb; 48(2):160-3. PubMed ID: 7745117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD30 expression utilization for the accuracy of classical Hodgkin's lymphoma staging.
    Flangea C; Potencz E; Mihăescu R; Anghel A; Gîju S; Motoc M; Dogaru C
    Rom J Morphol Embryol; 2006; 47(2):113-7. PubMed ID: 17106517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting cellular FLICE-like inhibitory protein as a novel approach to the treatment of Hodgkin's lymphoma.
    Dutton A; Burns AT; Young LS; Murray PG
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):911-9. PubMed ID: 16761935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA Superresolution Structure of Reed-Sternberg Cells Differs Between Long-Lasting Remission Versus Relapsing Hodgkin's Lymphoma Patients.
    Righolt CH; Knecht H; Mai S
    J Cell Biochem; 2016 Jul; 117(7):1633-7. PubMed ID: 26639515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Managing Hodgkin lymphoma without chemotherapy: a novel, yet 'welcomed', challenge.
    Kourie HR; Tabchi S; Kattan J
    Future Oncol; 2016 Jun; 12(12):1435-7. PubMed ID: 27117227
    [No Abstract]   [Full Text] [Related]  

  • 38. The biological environment of Hodgkin's lymphoma and the role of the chemokine CCL17/TARC.
    Hnátková M; Mociková H; Trnený M; Zivný J
    Prague Med Rep; 2009; 110(1):35-41. PubMed ID: 19591376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fascin, a sensitive new marker for Reed-Sternberg cells of hodgkin's disease. Evidence for a dendritic or B cell derivation?
    Pinkus GS; Pinkus JL; Langhoff E; Matsumura F; Yamashiro S; Mosialos G; Said JW
    Am J Pathol; 1997 Feb; 150(2):543-62. PubMed ID: 9033270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hodgkin's lymphoma: the role of cell surface receptors in regulation of tumor cell fate.
    Yurchenko M; Sidorenko SP
    Exp Oncol; 2010 Dec; 32(4):214-23. PubMed ID: 21270747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.